CD274 and non-small cell lung carcinoma: In 2016, another checkpoint inhibitor (atezolizumab, a programmed cell death-ligand 1 [PD-L1]) received its approval from FDA for first-line NSCLC treatment in patients with high PD-L1 expressing tumors [189,195,196,197,198].